Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer
Tumori Journal · 2026-10 · 112 (5) · 473-477
DOI: 10.1177/03008916261454865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumori Journal, online erschienen am 30.07.2026. Verfasst von Chiara Benvenuti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Breast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and aim There is limited data on the safety of switching between CDK4/6i to address toxicity-related permanent discontinuation in patients with HR+/HER2- advanced breast cancer (ABC). To overcome this issue, this international observational study included consecutive HR+/HER2- ABC patients treated with CDK4/6i at two cancer centers, who switched the CDK4/6i for toxicity. The study aimed to evaluate the safety, feasibility, and clinical impact of this approach. Results Among 1413 patients, 67 (4.5%) switched CDK4/6i due to toxicity. The median time to switch was three months. Adverse events leading to switch were mainly hematologic and hepatic. Recurrence of the same toxicity occurred in 30% of patients, but with lower severity for neutropenia (p=0.047) and hepatotoxicity (p=0.005). Notably, among the 67 patients who switched CDK4/6i, only seven (10%) ultimately required permanent discontinuation of the second CDK4/6i for toxicity, primarily for abemaciclib-induced diarrhea, suggesting that switching may represent a promising strategy to avoid treatment interruption. Median progression-free survival from the start of the first CDK4/6i was 16.8 months Conclusion In conclusion, switching CDK4/6i appears to be a safe and pragmatic strategy to address toxicity-related permanent discontinuation of CDK4/6i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Breast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Department of Medical Oncology, Gustave Roussy, Villejuif, France.
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy.
ORCID-Profile: Chiara Benvenuti, Riccardo Gerosa, Rita De Sanctis
Zitieren
APA
Benvenuti, C., Viansone, A., Jacobs, F., Grinda, T., Zeghondy, J., Gaudio, M., Clapis, L., Gerosa, R., Canzian, J., Poisson, C., Mokdad-Adi, M., Tiberio, P., Saltalamacchia, G., Zambelli, A., Santoro, A., Pistilli, B., & De Sanctis, R. (2026). Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer. Tumori Journal, 112(5), 473-477. https://doi.org/10.1177/03008916261454865
Vancouver
Benvenuti C, Viansone A, Jacobs F, Grinda T, Zeghondy J, Gaudio M, et al. Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer. Tumori Journal. 2026;112(5):473-477. doi:10.1177/03008916261454865
BibTeX
@article{Benvenuti2026,
author = {Benvenuti, Chiara and Viansone, Alessandro and Jacobs, Flavia and Grinda, Thomas and Zeghondy, Jean and Gaudio, Mariangela and Clapis, Laura and Gerosa, Riccardo and Canzian, Jacopo and Poisson, Caroline and Mokdad-Adi, Meriem and Tiberio, Paola and Saltalamacchia, Giuseppe and Zambelli, Alberto and Santoro, Armando and Pistilli, Barbara and De Sanctis, Rita},
title = {Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer},
journal = {Tumori Journal},
year = {2026},
volume = {112},
number = {5},
pages = {473--477},
doi = {10.1177/03008916261454865}
}
EUVIMED